Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Caspofungin bests fluconazole for antifungal prophylaxis in young AML patients

Key clinical point: Antifungal prophylaxis with caspofungin was better than fluconazole in children and young adults with acute myeloid leukemia (AML) at risk of invasive fungal disease.

Major finding: At 5-month follow-up, the cumulative incidence rate of probable or proven invasive fungal disease was significantly lower in the caspofungin arm (3.1%) compared with the fluconazole arm (7.2%).

Study details: A randomized clinical study of 517 children and young adults with AML.

Disclosures: The National Cancer Institute funded the study. The authors reported financial affiliations with Astellas, Celgene, Leadiant Biosciences, Merck, Nabriva Therapeutics, Novartis, Pfizer, Shire, and T2 Biosystems.

Citation:

Fisher BT et al. JAMA. 2019;322(17):1673-81.